eCite Digital Repository

PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events - economic implications?

Citation

Bottomley, J and Palmer, AJ and Williams, R and Dormandy, J and Massi-Benedetti, M, PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events - economic implications?, British Journal of Diabetes and Vascular Disease , 6, (2) pp. 63-70. ISSN 1474-6514 (2006) [Refereed Article]

DOI: doi:10.1177/14746514060060020401

Abstract

Economic value of medicines, medical devices and other technologies is an increasingly important consideration in healthcare management. Conducting high quality economic analyses alongside randomised controlled clinical trials (RCTs) is desirable since these offer timely information with high internal validity. The recent publication of the landmark PROactive study provides a relevant platform upon which to base a detailed economic evaluation of the possible additional benefit of pioglitazone over and above current best treatment in patients with type 2 diabetes with severe cardiovascular (CV) disease. Pioglitazone improved CV outcome and reduced the need to add insulin to existing therapy in individuals at high risk of further macrovascular events. The predefined economic analysis of this study using well-accepted methods will inform the cost effectiveness (CE) of pioglitazone confirming (or not) its value in the management of patients with type 2 diabetes with severe CV disease.

Item Details

Item Type:Refereed Article
Research Division:Economics
Research Group:Applied Economics
Research Field:Health Economics
Objective Division:Health
Objective Group:Health and Support Services
Objective Field:Health Policy Economic Outcomes
Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:74666
Year Published:2006
Deposited By:Research Division
Deposited On:2011-12-09
Last Modified:2011-12-13
Downloads:0

Repository Staff Only: item control page